Administering HPV Vaccine
- CDC recommends routine vaccination of girls and boys at ages 11 or 12.
- The vaccination series can be started at age 9 years
- HPV vaccines are administered as a 2-dose series (0, 6-12 months) for most persons who initiate vaccination at ages 9 through 14 years, and a 3-dose series (0, 1-2, 6 months) for persons who initiate at ages 15 through 26 years, and for immunocompromised persons.
Below are the HPV vaccines that are licensed by the U.S. Food and Drug Administration (FDA) since 2006.
|Year Licensed||June 2006 for females, and October 2009 for males||December 2014 for males and females|
|HPV types protected against by vaccine||HPV types 6, 11, 16, and 18||HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58|
|Adjuvant in vaccine||AAHS:
225 μg amorphous aluminum hydroxyphosphate sulfate
500 μg amorphous aluminum hydroxyphosphate sulfate
- Quadrivalent and 9-valent HPV vaccines protect against HPV 16 and 18, HPV types that cause about 66% of cervical cancers and the majority of other HPV-attributable cancers in the United States.
- 9-valent HPV vaccine targets five additional cancer-causing types, which account for about 15% of cervical cancers.
- Quadrivalent and 9-valent HPV vaccine also protect against HPV 6 and 11, HPV types that cause most anogenital warts.
The additional five types in 9-valent HPV vaccine account for a higher proportion of HPV-associated cancers in women compared with men, and also cause cervical precancers in women. Therefore, the additional protection from 9-valent HPV vaccine will mostly benefit women.
Administering Vaccines: Dose, Route, Site and Needle Size
Immunization Action Coalition
- Shake well before use. Thorough agitation immediately before administration is necessary to maintain suspension of the vaccine.
- Do not dilute or mix with other vaccines.
- After thorough agitation, HPV is a white, cloudy liquid.
- Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration.
- Do not use the product if particulates are present or if it appears discolored.
HPV vaccines should be administered intramuscularly in the deltoid region of the upper arm or in the higher anterolateral area of the thigh. The preferred site of administration is the deltoid region of the upper arm. Do not administer this product intravenously, intradermally, or subcutaneously.
|Recommended number of doses||Recommended dosing schedule||Population|
|2||0, 6–12 months*||Persons initiating vaccination at ages 9 through 14 years, except immunocompromised persons|
|3||0, 1–2, 6 months**||Persons initiating vaccination at ages 15 through 26 years, and immunocompromised persons initiating vaccination at ages 9 through 26 years|
* In a 2-dose schedule of HPV vaccine, the minimum interval is 5 months between the first and second dose
** In a 3-dose schedule of HPV vaccine, the minimum intervals are 4 weeks between the first and second dose, 12 weeks between the second and third dose, and 5 months between the first and third dose
HPV vaccine may be given at the same time as other vaccines.